The Swiss specialty biopharmaceutical company, Lumavita AG, has topped up a recent Series A funding round with CHF 6 million, bringing the total amount raised for commercialising its lead antibiotic product to CHF 24 million.
Eli Lilly has launched a new web-based initiative to capture independent drug research from universities and biotechnology companies that might eventually form the basis for future collaborations or licensing deals.
Pharming Group NV has expanded its equity by negotiating the conversion of some of its convertible debt into shares and by issuing about one million new shares from a stand-by equity facility.
GW Pharmaceuticals Plc, which has a cannabinoid product for multiple sclerosis in registration in Europe, has entered an exclusive strategic alliance with a professor at the University of Buckingham to investigate cannabinoids for metabolic disease.
Boehringer Ingelheim of Germany has announced plans to collaborate with the privately-held US firm, Vitae Pharmaceuticals Inc, to investigate beta-secretase inhibitors for the treatment of Alzheimer’s disease.
Allergy Therapeutics Plc is proposing to raise up to £22.4 million in a private share placement which would give a group of South American investors up to 49.65% of the group’s enlarged share capital.
A US company with novel technology for making peptide drugs has received $40 million in a Series D funding from a syndicate that includes the venture capital arms of four major pharmaceutical companies.
A British medical discovery company with 25 employees, a history of losses and no products under clinical development is about to raise £50 million through a share sale on Britain’s junior stock market
The Wellcome Trust has awarded €5.15 million to a vaccine institute run by Novartis AG to investigate a new bivalent vaccine for Typhoid fever.
The US Food and Drug Administration has asked Genmab A/S for an updated analysis of safety data for the monoclonal antibody, zalutumumab, which is being investigated for head and neck cancer.